Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Recruiting Phase 1 Trials for Osimertinib (DB09330)

IndicationStatusPhase
DBCOND0115716 (Stage IIIB Lung Non-Small Cell Cancer AJCC v7)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02520778Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerTreatment
NCT02503722Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase InhibitorTreatment